Martei YM, Chen K, Obasohan M, Mamtani R, Aakhus E, Shulman LN, Hubbard RA, Clark A. Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer , JNCI Cancer Spectr: 2026

Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Narayan V, Mei L, Takvorian S, Haas NB, Parikh RB, Mistry R, Mamtani R. OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care , Oncologist: 2026

Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA. Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes , Stat Med, 45: 2026

Litt H, Mehta P, Sahni A, Mamtani R. FDA-authorized oncology artificial intelligence and machine learning devices and their clinical evidence: A cross-sectional analysis , J Cancer Policy, 48: 2026,100743

Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, O'Neil B, D'Souza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang Y. Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer , Proc Natl Acad Sci U S A, 123: 2026,e2533449123

Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Parikh RB, Narayan V, Mei L, Takvorian SU, Balzer Haas N, Mistry R, and Mamtani R. OncoEducate: A pilot study of generative AI to support patient education in GU cancer care. , 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA., 44(7): 2026,713

Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R. Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis , Clin Genitourin Cancer: 2026

Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, Robinson TJ, Ma S, Mamtani R, Presley CJ, Wang SY, Kunst N, Gross CP, Dinan MA. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling , J Natl Compr Canc Netw, 24: 2026,e257131

Chow RD, Sedhom R, Mamtani R. Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer , JAMA Oncol: 2025

Litt HK, Mamtani R, Chow RD. Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction , Urol Oncol: 2025